Αποτελέσματα Αναζήτησης
Standardize the approach to screening and management of hyperbilirubinemia in neonates ≥ 35 weeks gestational age (GA) across the consortium hospitals using current practice standards and best available evidence. Improve quality and safety of care for neonates ≥ 35 weeks GA with hyperbilirubinemia; specifically:
5 Αυγ 2022 · This clinical practice guideline emphasizes the opportunities for primary prevention (eg, treatment to prevent isoimmune hemolytic disease, adequate breastfeeding support), the need to obtain an accurate history and physical examination to determine the presence of hyperbilirubinemia and hyperbilirubinemia neurotoxicity risk factors, the ...
1 Μαρ 2024 · The recent AAP guideline emphasizes the importance of visually assessing all infants for jaundice every 12 h after birth until discharge. If an infant appears jaundiced within 24 h of birth, clinicians should immediately obtain a transcutaneous bilirubin (TcB) or TSB.
March 2022. Outcomes/Goals. Identify and initiate prompt treatment of infants less than 14 days with jaundice/ suspected hyperbilirubinemia according to Northern California Neonatal Consortium (NCNC) guidelines. Support a team-oriented approach to efficient and timely evaluation and work-up.
29 Δεκ 2022 · Neonatal jaundice characterized by yellowish discoloration of the skin caused by hyperbilirubinemia affects up to 60% of term neonates and 80% of neonates with a gestational age of 35 weeks or more in the first two weeks after birth [ 1 ].
28 Αυγ 2023 · Our QI project shows that implementation of the NCNC neonatal hyperbilirubinemia guidelines that use higher phototherapy thresholds is feasible and reduces TSB testing and phototherapy treatment of hyperbilirubinemia.
26 Οκτ 2018 · Progressive familial intrahepatic cholestasis (PFIC) is the prototype of genetic liver diseases manifesting jaundice in early childhood, progressive liver fibrosis/cirrhosis, and failure to thrive. The first three types of PFICs identified (PFIC1, PFIC2, and PFIC3) represent defects in FIC1 (ATP8B1), BSEP (ABCB11), or MDR3 (ABCB4).
